CYP3A4 Cancer Research Results
CYP3A4, CYP3A4: Click to Expand ⟱
| Source: |
| Type: |
CYP3A4 is the most abundant cytochrome P450 enzyme in the liver and is also expressed in extrahepatic tissues.
– It metabolizes a wide range of drugs and endogenous substrates, including hormones.
– In some studies, higher CYP3A4 expression has been correlated with poorer response to treatment and potentially worse survival.
|
Scientific Papers found: Click to Expand⟱
*BioAv↓, Half-Life∅, *BioAv↓, Dose∅, eff↑, CYP1A2↓, CYP2C9↓, CYP3A4↓,
CYP3A4↓, Apoptosis↑, AntiTum↑,
Dose↝, BioAv↑, Half-Life↑, CYP3A4↓, PSA↓,
P450↓, CYP3A4↓, CYP2C9↓,
AntiCan↑, toxicity↓, ChemoSen↑, chemoP↑, TumCCA↑, TumCD↑, TumCI↓, angioG↓, Ferroptosis↑, Imm↑, MOMP↑, Cyt‑c↑, Casp↑, cl‑Casp3↑, cl‑Casp9↑, cl‑PARP↑, Apoptosis↑, ROS↑, TumAuto↑, GPx4↓, xCT/SLC7A11↓, RadioS↑, NRF2↓, HO-1↓, HSP90↓, Dose↝, Dose↝, BioAv↓, BioAv↝, CYP3A4↓, *toxicity↑, *toxicity↝,
| - |
in-vitro, |
BC, |
MCF7 |
|
|
|
- |
in-vitro, |
Liver, |
HepG2 |
|
|
|
- |
in-vitro, |
Ovarian, |
SKOV3 |
|
|
|
ChemoSen↑, CYP3A4↓, PXR, NR1I2↓, GSTA1↓, MDR1↓, MRP1/ABCC1↓, ABCG2↓,
Risk↓, AntiCan↑, TumCP↓, TumMeta↓, ChemoSen↑, *BioAv↑, *other↝, *Dose↝, Dose↓, *BioAv↑, *Dose↝, *Half-Life↝, *toxicity↝, GSH↓, ROS↑, CYP1A1↑, CYP1A2↑, P450↓, CYP2E1↑, CYP3A4↓, CYP2A3/CYP2A6↓, *ROS↓, *GPx1↑, *SOD1↑, *SOD2↑, Akt↓, EGFR↓, HER2/EBBR2↓, P53↑, Telomerase↓, selectivity↑, MMP↓, Cyt‑c↑, Apoptosis↑, DR4↑, Fas↑, XIAP↓, survivin↓, TumAuto↑, Hif1a↓, angioG↓, MMPs↓, ERK↓, NF-kB↓, EMT↓, TumCI↓, TumCMig↓, Glycolysis↓, ATP↓, selectivity↑, *antiOx↑, Dose↝, other↝, OCR↓, GSH↓, ITGB1↓, ITGB6↓, ChemoSen↑,
TumCCA↑, CYP1A1↓, CYP3A4↓, Cyt‑c↑, Casp9↑, Apoptosis↑, ROS↑, MAPK↑, P53↑, BAX↑, ChemoSen↑, HDAC↓, GSH↓, HO-1↑,
Showing Research Papers: 1 to 8 of 8
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8
Pathway results for Effect on Cancer / Diseased Cells:
NA, unassigned(tgid=0) ⓘ
PXR, NR1I2↓, 1,
Redox & Oxidative Stress(tgid=1) ⓘ
CYP1A1↓, 1, CYP1A1↑, 1, CYP2E1↑, 1, Ferroptosis↑, 1, GPx4↓, 1, GSH↓, 3, GSTA1↓, 1, HO-1↓, 1, HO-1↑, 1, NRF2↓, 1, ROS↑, 3, xCT/SLC7A11↓, 1,
Mitochondria & Bioenergetics(tgid=3) ⓘ
ATP↓, 1, MMP↓, 1, OCR↓, 1, XIAP↓, 1,
Core Metabolism/Glycolysis(tgid=4) ⓘ
CYP3A4↓, 8, Glycolysis↓, 1,
Cell Death(tgid=5) ⓘ
Akt↓, 1, Apoptosis↑, 4, BAX↑, 1, Casp↑, 1, cl‑Casp3↑, 1, Casp9↑, 1, cl‑Casp9↑, 1, Cyt‑c↑, 3, DR4↑, 1, Fas↑, 1, Ferroptosis↑, 1, MAPK↑, 1, MOMP↑, 1, survivin↓, 1, Telomerase↓, 1, TumCD↑, 1,
Kinase & Signal Transduction(tgid=6) ⓘ
HER2/EBBR2↓, 1,
Transcription & Epigenetics(tgid=7) ⓘ
other↝, 1,
Protein Folding & ER Stress(tgid=8) ⓘ
HSP90↓, 1,
Autophagy & Lysosomes(tgid=9) ⓘ
TumAuto↑, 2,
DNA Damage & Repair(tgid=10) ⓘ
P53↑, 2, cl‑PARP↑, 1,
Cell Cycle & Senescence(tgid=11) ⓘ
TumCCA↑, 2,
Proliferation, Differentiation & Cell State(tgid=12) ⓘ
EMT↓, 1, ERK↓, 1, HDAC↓, 1,
Migration(tgid=13) ⓘ
ITGB1↓, 1, ITGB6↓, 1, MMPs↓, 1, TumCI↓, 2, TumCMig↓, 1, TumCP↓, 1, TumMeta↓, 1,
Angiogenesis & Vasculature(tgid=14) ⓘ
angioG↓, 2, EGFR↓, 1, Hif1a↓, 1,
Immune & Inflammatory Signaling(tgid=16) ⓘ
Imm↑, 1, NF-kB↓, 1, PSA↓, 1,
Drug Metabolism & Resistance(tgid=21) ⓘ
ABCG2↓, 1, BioAv↓, 1, BioAv↑, 1, BioAv↝, 1, ChemoSen↑, 5, CYP1A2↓, 1, CYP1A2↑, 1, CYP2A3/CYP2A6↓, 1, CYP2C9↓, 2, Dose↓, 1, Dose↝, 4, Dose∅, 1, eff↑, 1, Half-Life↑, 1, Half-Life∅, 1, MDR1↓, 1, MRP1/ABCC1↓, 1, P450↓, 2, RadioS↑, 1, selectivity↑, 2,
Clinical Biomarkers(tgid=22) ⓘ
EGFR↓, 1, HER2/EBBR2↓, 1, PSA↓, 1,
Functional Outcomes(tgid=23) ⓘ
AntiCan↑, 2, AntiTum↑, 1, chemoP↑, 1, Risk↓, 1, toxicity↓, 1,
Total Targets: 86
Pathway results for Effect on Normal Cells:
Redox & Oxidative Stress(tgid=1) ⓘ
antiOx↑, 1, GPx1↑, 1, ROS↓, 1, SOD1↑, 1, SOD2↑, 1,
Transcription & Epigenetics(tgid=7) ⓘ
other↝, 1,
Drug Metabolism & Resistance(tgid=21) ⓘ
BioAv↓, 2, BioAv↑, 2, Dose↝, 2, Half-Life↝, 1,
Functional Outcomes(tgid=23) ⓘ
toxicity↑, 1, toxicity↝, 2,
Total Targets: 12
Scientific Paper Hit Count for: CYP3A4, CYP3A4
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:0 prod#:% Target#:1131 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid
Home Page